Unlocking the Promise of Biology
Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies.
View Our Academic CollaborationsTwo Late-Stage Therapeutics for Multiple Oncology Indications with Unmet Medical Needs
VAL-083 is a structurally-unique small molecule targeting DNA to inhibit cancer cell replication and cell division, which leads to cell death. Like other established agents extensively studied by U.S. National Cancer Institute (NCI), such as cisplatin, paclitaxel and camptothecin, VAL-083 has been assessed in 42 Phase 1 and Phase 2 clinical trials sponsored by NCI.
REM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds.
An Experienced Team with a Track Record of Success
Kintara Therapeutics leadership team is committed to contributing to the battle against cancer by researching and developing novel cancer therapies that treat patients with significant unmet clinical need.